Washington University SPORE in Pancreatic Cancer

华盛顿大学 SPORE 在胰腺癌中的应用

• 批准号: 9146190
• 负责人: WILLIAM G HAWKINS
• 金额: $ 218.67万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-07-28 至 2021-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9146190
• 关键词: Antineoplastic Agents; Basic Science; Biometry; Cancer Biology; Cancer Center; Cancer Research Project; Cancer Vaccines; Clinic; Clinical; Clinical Sciences; Clinical Trials; Collaborations; Dendritic Cells; Development; Diagnosis; Disabled Persons; Disease; Drug Targeting; Ensure; Environment; Female; Fostering; Genomics; Goals; Image; Imaging Techniques; Immune response; Immunologics; Immunology; Immunosuppression; Immunotherapy; Individual; Institution; KRAS2 gene; Ligands; Malignant neoplasm of pancreas; Mentors; Minority; Mission; Monitor; Morbidity - disease rate; Myelogenous; Nebraska; North Carolina; Pancreatic Ductal Adenocarcinoma; Pathway interactions; Patients; Pharmaceutical Chemistry; Pharmaceutical Preparations; Process; Radiology Specialty; Recruitment Activity; Research; Research Infrastructure; Research Personnel; Research Project Grants; Resource Sharing; Resources; Science; Specialized Program of Research Excellence; Suppressor-Effector T-Lymphocytes; Testing; Therapeutic; Therapeutic Clinical Trial; Therapeutic Trials; Tissues; Training; Translational Research; Translations; Universities; Washington; Work; animal imaging; cancer therapy; career; clinical practice; design; drug development; improved; inhibitor/antagonist; innovation; inter-institutional; leukemia; malignant breast neoplasm; migration; mortality; mutant; novel; novel diagnostics; novel strategies; novel therapeutic intervention; novel therapeutics; patient population; preclinical study; prevent; programs; response; small molecule inhibitor; small molecule therapeutics; tumor; tumor microenvironment

PROJECT SUMMARY The Washington University Pancreatic Cancer Specialized Program of Research Excellence (SPORE) is a highly translational cancer research program focused entirely on the deadliest form of the disease, pancreatic ductal adenocarcinoma (PDAC). Our outstanding investigators have complementary expertise in basic and clinical sciences, and our teams leverage individual expertise in immunology, drug development, genomics, and imaging to develop novel diagnostic and therapeutic approaches to PDAC. This SPORE includes four research projects, an administrative core, two shared-resources cores, and developmental research and career enhancement programs. With the help of our External and Internal Advisory Boards, we have intentionally selected the projects that have the greatest potential to impact PDAC. All four of our selected projects include a therapeutic trial, and two take advantage of immunologic discoveries made at WU. We have two projects that utilize small molecule inhibitors of pathways that are known to be active in PDAC. The four projects in our application are designed to have significant potential to change clinical practice within five years. Project 1: Overcoming Tumor-Induced Immune Suppression to Improve Responses to Immunotherapy Project 2: Clinical Development of the Pancreatic Cancer Drug Conjugate SW V-49 Project 3: Combination Inhibition of ERK for Pancreatic Cancer Treatment Project 4: Translation and Preclinical Studies of a Personalized Pancreatic Cancer Vaccine Our long-term goal is to improve survival of patients diagnosed with PDAC. To achieve this, we will promote institutional and inter-institutional collaborative science, with an emphasis on translation. We expect that no singular approach will solve PDAC, and fully commit to supporting the development of novel ideas and young investigators. Our SPORE will provide access to pancreatic cancer-specific resources to facilitate this mission.

项目总结 华盛顿大学胰腺癌专业研究计划(孢子)是一项 高度转化性癌症研究项目完全聚焦于这种疾病最致命的形式--胰腺 导管腺癌(PDAC)。我们优秀的调查人员在基础和基础方面拥有互补的专业知识 临床科学，我们的团队利用个人在免疫学、药物开发、基因组学、 和成像，以开发PDAC的新诊断和治疗方法。 该孢子包括四个研究项目、一个管理核心、两个共享资源核心和 发展研究和职业提升计划。借助我们的外部和内部 在咨询委员会中，我们特意选择了对PDAC有最大影响潜力的项目。 我们选择的所有四个项目都包括一项治疗试验，其中两项利用了免疫学发现 吴国制造。我们有两个项目利用小分子途径的抑制剂，这是已知的 在PDAC中活动。我们应用程序中的四个项目旨在极大地改变临床 在五年内实践。 项目1：克服肿瘤引起的免疫抑制以改善对免疫治疗的反应 项目2：胰腺癌药物结合物SW V-49的临床开发 项目3：ERK联合抑制治疗胰腺癌 项目4：个体化胰腺癌疫苗的翻译和临床前研究 我们的长期目标是提高诊断为PDAC的患者的存活率。为了实现这一目标，我们将推动 机构和机构间协作科学，重点是翻译。我们预计不会 单一的方法将解决PDAC，并全力致力于支持新奇想法的发展和年轻 调查人员。我们的孢子将提供对胰腺癌特定资源的访问，以促进这一任务。